Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)



Recordati Rare Diseases announced today the commercial availability of Isturisa® (osilodrostat). Over 50 patients with Cushing’s syndrome have already been initiated on Isturisa® under temporary authorization for use (ATU), granted by the French National......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Tuesday, 2 June
Share |